Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Borealis Biosciences

Request full access

Borealis Biosciences was established on the belief that recent scientific and translational advancements are unlocking the potential of RNA medicines to treat kidney diseases and more

Vancouver, CanadaFounded 2024Biotech & Life Sciences

About Borealis Biosciences

Borealis Biosciences is a Vancouver-based biotechnology firm focused on creating next-generation RNA-based medicines to treat kidney diseases. The company launched in August 2024, emerging from stealth with $150 million in a combined Series A financing and strategic research collaboration funding. The primary investors are founding investor Versant Ventures and the pharmaceutical company Novartis AG.

The company's genesis is directly linked to Chinook Therapeutics, a successful kidney disease company also founded by Versant Ventures in 2019 and later acquired by Novartis in 2023 for up to $3.5 billion. Following the acquisition, Novartis and Versant collaborated to establish Borealis as an independent entity, built around key members of Chinook's Vancouver-based research team. This strategic formation involved Novartis divesting the former 23,000-square-foot Chinook operating site in Vancouver, transferring certain employees, and investing in the new company. The initial team of over 25 individuals consists of experienced drug developers with deep expertise in kidney disease, RNA therapeutics, and translational data science.

Borealis' business model is centered on the discovery and development of RNA therapeutics for kidney diseases that have been difficult to address with traditional small molecules or biologics. The company utilizes advanced approaches in patient stratification, genetically defined targets, and RNA chemistry to deliver therapeutic payloads to specific kidney cell types. Its revenue and growth are supported by a strategic collaboration with Novartis. As part of this agreement, Novartis has committed up to $100 million in upfront and near-term research funding and holds an option to acquire two future development-ready programs from Borealis for a total consideration of up to $750 million, including milestones.

The company's core product focus is on xRNA, a technology platform that can target the body's natural mRNA to modulate the production of proteins that cause disease. Borealis aims to address significant unmet needs for patients with various kidney diseases, including IgA nephropathy, by targeting causal disease drivers that have previously been considered undruggable. The company operates from a state-of-the-art facility in Vancouver, which includes labs for molecular and cellular biology, chemistry, and analytical capabilities, providing a robust foundation for its research and development objectives.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2024
Headquarters
Vancouver, Canada
Employees
54
Open positions
2
Dealroom signal
27.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Dec 2024 $30M $750M Westlake Village BioPartners ↗
SERIES AOther financing Aug 2024 $150M $600M Versant Ventures · Novartis ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Borealis Biosciences website traffic

Latest recorded traffic for Borealis Biosciences is 860 monthly website visits, down 42.7% over the last three months.

Latest monthly visits860 3-month web change-42.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
SecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform Minneapolis, United States Operational 19 $17M $28M
FunPepFunPep is an Industry-university collaboration bioventure company Ibaraki, Japan Operational
Arterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors Atlanta, United States Operational
LysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology Lafayette, United States Operational
TAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology Tokyo, Japan Acquired
Amygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction Palo Alto, United States Operational
AnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products Huangpu, China Acquired
Contraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics Siena, Italy Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Borealis Biosciences in the Vancouver ecosystem

Live from Dealroom

The Borealis Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇦 Canada81.4%
🇺🇸 United States18.6%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Borealis Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Borealis Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.